Nuclear factor-κB maintains TRAIL resistance in human pancreatic cancer cells
Sanaz Khanbolooki(The University of Texas MD Anderson Cancer Center), David J. McConkey(Johns Hopkins University), Thiruvengadam Arumugam(The University of Texas MD Anderson Cancer Center), Razelle Kurzrock(Medical College of Wisconsin), Steffan T. Nawrocki(University of Arizona), Maria Simona Pino(Massachusetts General Hospital), Craig D. Logsdon(The University of Texas MD Anderson Cancer Center), James L. Abbruzzese(Duke University), Robert H.I. Andtbacka(Huntsman Cancer Institute)
Cited by 134
Related Papers
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
|Molecular Cancer Therapeutics|2017|2.4k
PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
|Molecular Cancer Therapeutics|2015|2.3k
A Consensus Molecular Classification of Muscle-invasive Bladder Cancer
|European Urology|2019|1.4k